Experts and Doctors on papillomavirus infections in Cape Town, Western Cape, South Africa


Locale: Cape Town, Western Cape, South Africa
Topic: papillomavirus infections

Top Publications

  1. Denny L, Kuhn L, Hu C, Tsai W, Wright T. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010;102:1557-67 pubmed publisher
    ..1%) arms. In this trial, a screen-and-treat approach using HPV DNA testing identified and treated prevalent cases of CIN2+ and appeared to reduce the number of incident cases of CIN2+ that developed more than 12 months after cryotherapy. ..
  2. Kuguyo O, Matimba A, Tsikai N, Magwali T, Madziyire M, Gidiri M, et al. Cervical cancer in Zimbabwe: a situation analysis. Pan Afr Med J. 2017;27:215 pubmed publisher
    ..Limited resources as well as the high HIV prevalence are contributors to the high burden of cervical cancer. This paper aims to analyse the policies, frameworks and current practices in the management of cervical cancer in Zimbabwe...
  3. Mbulawa Z, Wilkin T, Goeieman B, Jong E, Michelow P, Swarts A, et al. Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV Assays in South African HIV-Infected Women. Am J Clin Pathol. 2017;148:148-153 pubmed publisher
    ..1, 95% CI: 1.4-12, P = .01) and HPV51/59 (OR: 2.8, 95% CI: 1.1-7.6, P = .04) were independently associated with anal HSIL. Xpert HPV typing is a promising anal screening test in HIV-infected women that performs similarly to hc2. ..
  4. Yanez R, Lamprecht R, Granadillo M, Weber B, Torrens I, Rybicki E, et al. Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana. PLoS ONE. 2017;12:e0183177 pubmed publisher
  5. Sankaranarayanan R, Anorlu R, Sangwa Lugoma G, Denny L. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine. 2013;31 Suppl 5:F47-52 pubmed publisher
    ..Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. ..
  6. Bosch F, Broker T, Forman D, Moscicki A, Gillison M, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 5:F1-31 pubmed publisher
    ..Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters. ..
  7. Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer. 2014;134:1389-98 pubmed publisher
    ..In conclusion, HPV16, 18, 45 and 35 were the most common HPV types in sub-Saharan African women with ICC and HPV infections were more common in HIV-positive women. ..
  8. Schäfer G, Kabanda S, van Rooyen B, Marusic M, Banks L, Parker M. The role of inflammation in HPV infection of the Oesophagus. BMC Cancer. 2013;13:185 pubmed publisher
    ..This study showed that although the carcinogen benzo-?-pyrene facilitated HPV pseudovirion uptake into cells in culture, HPV infectivity was independent of inflammation and seems to play only a minor role in oesophageal cancer. ..
  9. Hille J, Webster Cyriaque J, Palefski J, Raab Traub N. Mechanisms of expression of HHV8, EBV and HPV in selected HIV-associated oral lesions. Oral Dis. 2002;8 Suppl 2:161-8 pubmed
    ..The mechanisms of interaction between HIV and HPV are not fully understood. Expression of viral gene products is clearly important and necessary for the development of multiple AIDS-associated oral lesions...

More Information


  1. Chatterjee K, Dandara C, Hoffman M, Williamson A. CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer. 2010;10:278 pubmed publisher
    ..This result implies that the role of CCR2 is important in invasive cancer of the cervix but not in HPV infection or in the development of pre-cancers. ..
  2. Mbulawa Z, Coetzee D, Marais D, Kamupira M, Zwane E, Allan B, et al. Genital human papillomavirus prevalence and human papillomavirus concordance in heterosexual couples are positively associated with human immunodeficiency virus coinfection. J Infect Dis. 2009;199:1514-24 pubmed publisher
    ..In conclusion, HIV coinfection in one or both sexually active partners increased HPV prevalence and HPV type-specific concordance. ..
  3. Govan V, Rybicki E, Williamson A. Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas. Virol J. 2008;5:45 pubmed publisher
    ..05). This data demonstrates the therapeutic potential of PV VLPs in a well-understood animal model with potential important implications for human therapeutic vaccination for low-risk HPVs...
  4. Govan V, Loubser S, Saleh D, Hoffman M, Williamson A. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency. Int J Immunogenet. 2007;34:213-7 pubmed
    ..05) between the control groups of South Africa and other population groups. This result suggests that ethnic disparity may influence the levels of p53 produced. ..
  5. Govan V, Constant D, Hoffman M, Williamson A. The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer. 2006;6:24 pubmed
    ..However, as the distribution of the -308A TNF-alpha was notably different between the control groups of South Africa and other population groups this result suggests that ethnic disparity may influence the levels of TNF-alpha produced. ..
  6. Govan V, Christensen N, Berkower C, Jacobs W, Williamson A. Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine. 2006;24:2087-93 pubmed
    ..5% of CRPV at serum dilutions of 1:200. These results provide evidence that BCG could potentially be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible prophylactic vaccine...
  7. Sinanovic E, Moodley J, Barone M, Mall S, Cleary S, Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine. 2009;27:6196-202 pubmed publisher
    ..To address the issue of affordability and cost-effectiveness, the pharmaceutical companies need to make a commitment to price reductions. ..
  8. Moodley J, Constant D, Hoffman M, Salimo A, Allan B, Rybicki E, et al. Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study. BMC Cancer. 2009;9:275 pubmed publisher
    ..Our results underscore the need for locally relevant, rigorous screening protocols for the increasing numbers of women accessing ARV therapy so that the benefits of ARVs are not partially offset by an excess risk in cervical cancer. ..
  9. Marais D, Gawarecki D, Allan B, Ahmed K, Altini L, Cassim N, et al. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antivir Ther. 2011;16:1219-26 pubmed publisher
    ..The prevalence of HR-HPV infection was lower in compliant Carraguard users than compliant placebo users. To our knowledge, this is the first report showing a negative association of HPV infection with a vaginal microbicide. ..
  10. Meiring T, Salimo A, Coetzee B, Maree H, Moodley J, Hitzeroth I, et al. Next-generation sequencing of cervical DNA detects human papillomavirus types not detected by commercial kits. Virol J. 2012;9:164 pubmed publisher
    ..The significance of these types in relation to cervical disease remains to be investigated. ..
  11. Denny L. Cervical cancer: prevention and treatment. Discov Med. 2012;14:125-31 pubmed
    ..Ongoing efforts to refine the characteristics of screening tests continue, as does implementation of current HPV vaccines for the primary prevention of cervical cancer. ..
  12. Denny L, Franceschi S, de Sanjose S, Heard I, Moscicki A, Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine. 2012;30 Suppl 5:F168-74 pubmed publisher
    ..This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. ..
  13. Kohl T, Hitzeroth I, Christensen N, Rybicki E. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. BMC Biotechnol. 2007;7:56 pubmed
    ..This has important and potentially negative implications for the production of HPV-11 vaccines in plants. ..
  14. Govan V, Williamson A. Rabbits immunised with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L2E7E2 genes induces regression of established papillomas. Virus Res. 2007;127:43-8 pubmed
    ..05). The findings in this study suggest that BCG could probably be used as a vaccine delivery vehicle for human papillomavirus proteins as a possible therapeutic vaccine...
  15. Marais D, Carrara H, Kay P, Ramjee G, Allan B, Williamson A. The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res. 2006;121:220-2 pubmed
    ..5 95% CI 1.0-11.8). We conclude that the use of nonoxynol-9 did not prevent genital HPV infection and could increase the virus' ability to infect or persist...